Autologous stem cell transplantation for relapsed/refractory diffuse large @entity1892 : efficacy in the rituximab XXXX and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.

@entity1892 @entity12497 @entity7971 @entity1
UNASSIGNED: In the @entity7971 of chemoimmunotherapy, the optimal treatment paradigm for relapsed and refractory diffuse large @entity1892 has been challenged. We reviewed the outcome of standard salvage therapy with an autologous stem cell transplant (autoSCT) over the last two decades and the outcome of @entity12497 ( @entity12497 ) in the most recent decade. AutoSCT recipients diagnosed between 1992 and 2002 (n=2737) were compared with those diagnosed between 2002 and 2010 (n=3980). @entity1 diagnosed after 2002 had a significantly lower non-relapse mortality (NRM) and relapse incidence (RI) and a superior PFS and overall survival (OS). A total of 4210 @entity1 diagnosed between 2002 and 2010 underwent either an autoSCT or an @entity12497 as their first transplant procedure. Two-hundred and thirty @entity1 received an @entity12497 (myeloablative (MACalloSCT) n=132, reduced intensity (RICalloSCT) n=98). The 4-year NRM rates were 7%, 20% and 27% for autoSCT, RICalloSCT and MACalloSCT, respectively. The 4-year RI was 45%, 40% and 38% for autoSCT, RICalloSCT and MACalloSCT, respectively (NS). The 4-year PFS were 48%, 52% and 35% for autoSCT, RICalloSCT and MACalloSCT, respectively. The 4-year OS was 60%, 52% and 38% for autoSCT, RIC @entity12497 and MACalloSCT, respectively. After adjustment for confounding factors NRM was significantly worse for @entity1 undergoing @entity12497 whilst there was no difference in the RI.Bone Marrow Transplantation advance online publication, 30 November 2015; doi:10.1038/bmt.2015.286.
